Treatment and prevention of rotavirus infection in children

Current Infectious Disease Reports

Volumn 15, Issue 3, 2013, Pages 242-250

  Dennehy, Penelope H ^a,b  

^a HASBRO CHILDREN'S HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Rotavirus; Rotavirus gastroenteritis; Rotavirus surveillance; Rotavirus vaccine

Indexed keywords

ACETORPHAN; INFUSION FLUID; LACTOBACILLUS VACCINE; NITAZOXANIDE; ONDANSETRON; PROBIOTIC AGENT; PROTEIN VP4; PROTEIN VP7; ROTAVIRUS VACCINE; VIRUS VACCINE;

ACUTE GASTROENTERITIS; AGE DISTRIBUTION; ARTICLE; AUSTRALIA; BRAZIL; CHILDHOOD MORTALITY; CIRCOVIRUS; CLINICAL TRIAL (TOPIC); DEHYDRATION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTROLYTE DISTURBANCE; EMERGENCY WARD; EPIDEMIOLOGICAL MONITORING; FLUID INTAKE; GENETIC VARIABILITY; HEALTH IMPACT ASSESSMENT; HEALTH PROGRAM; HERD IMMUNITY; HOSPITALIZATION; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INTUSSUSCEPTION; LACTOBACILLUS RHAMNOSUS; LONG QT SYNDROME; MEXICO; MORBIDITY; PARENTERAL NUTRITION; POPULATION RESEARCH; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHYDRATION; RISK BENEFIT ANALYSIS; ROTAVIRUS INFECTION; SEASONAL VARIATION; SPRING; SYMPTOMATOLOGY; TREND STUDY; UNITED STATES; VACCINE PRODUCTION; VIRAL GASTROENTERITIS; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION; VOMITING; WINTER;

EID: 84878688102     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0333-5     Document Type: Article

References (73)

1. Tate JE, Burton AH, Boschi-Pinto C, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(2):136-41.
2. Fischer TK, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993-2003. J Infect Dis. 2007;195(8):1117-25.
3. Malek MA, Curns AT, Holman RC, et al. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics. 2006;117(6):1887-92.
4. Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009;58(RR-2):1-25.
5. King CK, Glass R, Bresee JS, Duggan C. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep. 2003;52(RR-16):1-16.
6. Guarino A, Lo Vecchio A, Canani RB. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol. 2009;25(1):18-23.
7. Szajewska H, Dziechciarz P. Gastrointestinal infections in the pediatric population. Curr Opin Gastroenterol. 2010;26(1):36-44.
8. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011;45(Suppl):S149-153.
9. Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet. 2006;368(9530):124-9.
10. Rossignol JF, El-Gohary YM. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther. 2006;24(10):1423-30.
11. Teran CG, Teran-Escalera CN, Villarroel P. Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int J Infect Dis. 2009;13(4):518-23.
12. Szajewska H, Ruszczynski M, Chmielewska A, Wieczorek J. Systematic review: racecadotril in the treatment of acute diarrhoea in children. Aliment Pharmacol Ther. 2007;26(6):807-13.
13. Fedorowicz Z, Alhashimi D, Alhashimi H. Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. Aliment Pharmacol Ther. 2007;26(7):1086. author reply 1087.
14. Szajewska H, Gieruszczak-Bialek D, Dylag M. Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. Aliment Pharmacol Ther. 2007;25(4):393-400.
15. World Health Organization. Rotavirus vaccines:an update. Wkly Epidemiol Rec. 2009;84(50):533-40.
16. Committee on Infectious Diseases of the American Academy of Pediatrics. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics. 2009;123(5):1412-20.
17. •• Soares-Weiser K, Maclehose H, Bergman H, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2012;2:CD008521. This Cochrane systematic review evaluated rotavirus vaccines approved for use for preventing rotavirus diarrhea. Secondary objectives were to evaluate the efficacy of rotavirus vaccines on all-cause diarrhea, hospital admission, death, and safety profiles. The review found that RV1 and RV5 vaccines are effective in preventing rotavirus diarrhea.
18. • Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine. 2011;29(16):3061-6. Although this study found no overall increase in intussusception following receipt of rotavirus vaccine, there was some evidence of an elevated risk following the first dose of both vaccines.
19. • Patel MM, Lopez-Collada VR, Bulhoes MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011;364(24):2283-92. An increased risk of intussusception after the first dose of RV1 was identified among infants in Mexico. No significant risk was found after the first dose among infants in Brazil.
20. • Velazquez FR, Colindres RE, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J. 2012;31(7):736-44. This is the largest surveillance study for intussusception after rotavirus vaccination to date. A temporal increase in the risk for intussusception was seen within 7 days of administration of the first vaccine dose.
21. Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA. 2012;307(6):598-604.
22. Loughlin J, Mast TC, Doherty MC, Wang FT, Wong J, Seeger JD. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. Pediatr Infect Dis J. 2012;31(3):292-6.
23. •• Yen C, Tate JE, Steiner CA, Cortese MM, Patel MM, Parashar UD. Trends in intussusception hospitalizations among US infants before and after implementation of the rotavirus vaccination program, 2000-2009. J Infect Dis. 2012;206(1):41-8. This study examined age-specific trends in population-level intussusception hospitalization rates before (2000-2005) and after (2007-2009) rotavirus vaccine introduction among infants in 26 U.S. states comprising 75 % of the birth cohort and found, following rotavirus vaccine introduction, a small increase in intussusception rates was seen among U.S. infants 8-11 weeks of age.
24. •• Desai R, Cortese MM, Meltzer MI, et al. Potential intussusception risk versus benefits of rotavirus vaccination in the United States. Pediatr Infect Dis J. 2013;32(1):1-7. The authors assumed a risk similar to international settings and compared potential vaccine-associated intussusception cases with benefits of prevention of rotavirus gastroenteritis by a fully implemented U.S. rotavirus vaccine program. They found that if an intussusception risk similar to that seen internationally exists in the United States, it is substantially exceeded by the benefits of rotavirus disease burden averted by vaccination.
25. Victoria JG, Wang C, Jones MS, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol. 2010;84(12):6033-40.
26. McClenahan SD, Krause PR, Uhlenhaut C. Molecular and infectivity studies of porcine circovirus in vaccines. Vaccine. 2011;29(29-30):4745-53.
27. Dore DD, Turnbull BR, Seeger JD. Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments. Pharmacoepidemiol Drug Saf. 2012;21(4):415-9.
28. Payne DC, Humiston S, Opel D, et al. A multi-center, qualitative assessment of pediatrician and maternal perspectives on rotavirus vaccines and the detection of Porcine circovirus. BMC Pediatr. 2011;11:83.
29. • Desai R, Lopman BA, Shimshoni Y, Harris JP, Patel MM, Parashar UD. Use of Internet search data to monitor impact of rotavirus vaccination in the United States. Clin Infect Dis. 2012;54(9):e115-118. Google-based Internet query share (IQS) for rotavirus search terms correlated well with U.S. rotavirus laboratory detections from 2004 to 2010 capturing the reduction observed during postvaccine years (2008-2010). The authors conclude that IQS analysis could become an inexpensive and reliable supplement for monitoring the impact of rotavirus vaccination in the United States.
30. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics. 2010;125(2):e199-207.
31. Boom JA, Tate JE, Sahni LC, et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J. 2010;29(12):1133-5.
32. Desai SN, Esposito DB, Shapiro ED, Dennehy PH, Vazquez M. Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. Vaccine. 2010;28(47):7501-6.
33. Eberly MD, Gorman GH, Eide MB, Olsen CH, Rajnik M. The effect of rotavirus immunization on rotavirus gastroenteritis hospitalization rates in military dependents. Vaccine. 2011;29(4):650-9.
34. Guh AY, Hadler JL. Use of the state immunization information system to assess rotavirus vaccine effectiveness in Connecticut, 2006-2008. Vaccine. 2011;29(37):6155-8.
35. Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics. 2011;128(2):e267-275.
36. Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics. 2010;125(2):e208-213.
37. Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J. 2010;29(10):957-63.
38. Begue RE, Perrin K. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. Pediatrics. 2010;126(1):e40-45.
39. Chang HG, Smith PF, Tserenpuntsag B, Markey K, Parashar U, Morse DL. Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine. 2010;28(3):754-8.
40. Clark HF, Lawley D, Matthijnssens J, DiNubile MJ, Hodinka RL. Sustained decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia in the new rotavirus vaccine era. Pediatr Infect Dis J. 2010;29(8):699-702.
41. • Cortes JE, Curns AT, Tate JE, et al. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Engl J Med. 2011;365(12):1108-17. This article notes that diarrhea-associated health-care utilization and medical expenditures for children have decreased substantially since the introduction of rotavirus vaccine in the United States.
42. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis. 2010;201(11):1617-24.
43. Custodio H, Masnita-Iusan C, Wludyka P, Rathore MH. Change in rotavirus epidemiology in northeast Florida after the introduction of rotavirus vaccine. Pediatr Infect Dis J. 2010;29(8):766-7.
44. Desai R, Curns AT, Steiner CA, Tate JE, Patel MM, Parashar UD. All-cause gastroenteritis and rotavirus-coded hospitalizations among US children, 2000-2009. Clin Infect Dis. 2012;55(4):e28-34.
45. Payne DC, Staat MA, Edwards KM, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis. 2011;53(3):245-53.
46. Staat MA, Rice MA, Donauer S, et al. Estimating the rotavirus hospitalization disease burden and trends, using capture-recapture methods. Pediatr Infect Dis J. 2010;29(12):1083-6.
47. Williams DJ, Edwards KM, Payne DC, Manning J, Parashar UD, Lopman BA. Decline in gastroenteritis-related triage calls after rotavirus vaccine licensure. Pediatrics. 2012;130(4):e872-878.
48. Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics. 2009;124(2):465-71.
49. • Tate JE, Mutuc JD, Panozzo CA, et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J. 2011;30(1 Suppl):S30-34. This study reports that rotavirus activity was substantially diminished during the 2009-2010 rotavirus season, as compared with the prevaccine baseline and the two previous postvaccine introduction seasons. These sustained declines over three rotavirus seasons reaffirm the health benefits of the U.S. rotavirus vaccination program.
50. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis. 2011;204(7):980-6.
51. • Glass RI. Unexpected benefits of rotavirus vaccination in the United States. J Infect Dis. 2011;204(7):975-7. This commentary discusses the surprises about the epidemiology of disease revealed by the rotavirus vaccine program in the United States. including the herd effect of the vaccination program, that rotavirus is a greater than anticipated cause of gastroenteritis in older children and adults and that young children may be the source of infections in older children and adults.
52. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33.
53. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370(9601):1757-63.
54. Vesikari T, Itzler R, Karvonen A, et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine. 2009;28(2):345-51.
55. Turcios RM, Curns AT, Holman RC, et al. Temporal and geographic trends of rotavirus activity in the United States, 1997-2004. Pediatr Infect Dis J. 2006;25(5):451-4.
56. Curns AT, Panozzo CA, Tate JE, et al. Remarkable postvaccination spatiotemporal changes in United States rotavirus activity. Pediatr Infect Dis J. 2011;30(1 Suppl):S54-55.
57. • Banyai K, Laszlo B, Duque J, et al. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine. 2012;30 Suppl 1:A122-130. This study provides the most comprehensive, up-to-date information on rotavirus strain surveillance in the pre-rotavirus-vaccine era and will provide useful background to examine the impact of rotavirus vaccine introduction on future strain prevalence.
58. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11-22.
59. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606-14.
60. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):615-23.
61. • Breiman RF, Zaman K, Armah G, et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine. 2012;30 Suppl 1:A24-29. This analysis combines data from the five sites that strengthens the precision of vaccine efficacy estimates and reveals rising vaccine efficacy with increased rotavirus gastroenteritis severity.
62. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis. 2010;201(3):363-9.
63. Justino MC, Linhares AC, Lanzieri TM, et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belem, Brazil. Pediatr Infect Dis J. 2011;30(5):396-401.
64. Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis. 2011;52(2):191-9.
65. Field EJ, Vally H, Grimwood K, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics. 2010;126(3):e506-512.
66. Yen C, Figueroa JR, Uribe ES, et al. Monovalent Rotavirus Vaccine Provides Protection Against an Emerging Fully Heterotypic G9P[4] Rotavirus Strain in Mexico. J Infect Dis. 2011;204(5):783-6.
67. Justino MC, Araujo EC, van Doorn LJ, et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Mem Inst Oswaldo Cruz. 2012;107(7):846-53.
68. Carvalho-Costa FA, Volotao Ede M, de Assis RM, et al. Laboratory-based rotavirus surveillance during the introduction of a vaccination program, Brazil, 2005-2009. Pediatr Infect Dis J. 2011;30(1 Suppl):S35-41.
69. Hull JJ, Teel EN, Kerin TK, et al. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis J. 2011;30(1 Suppl):S42-47.
70. Kirkwood CD, Boniface K, Barnes GL, Bishop RF. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix(R) and RotaTeq(R), into the National Immunization Program of Australia. Pediatr Infect Dis J. 2011;30(1 Suppl):S48-53.
71. Pitzer VE, Patel MM, Lopman BA, Viboud C, Parashar UD, Grenfell BT. Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions. Proc Natl Acad Sci U S A. 2011;108(48):19353-8.
72. Boom JA, Sahni LC, Payne DC, et al. Symptomatic infection and detection of vaccine and vaccine-reassortant rotavirus strains in 5 children: a case series. J Infect Dis. 2012;206(8):1275-9.
73. Donato CM, Ch'ng LS, Boniface KF, et al. Identification of strains of RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J Infect Dis. 2012;206(3):377-83.